MCID: SYS051
MIFTS: 22

Systemic Lupus Erythematosus 4

Categories: Genetic diseases, Rare diseases, Nephrological diseases, Immune diseases, Bone diseases, Skin diseases

Aliases & Classifications for Systemic Lupus Erythematosus 4

MalaCards integrated aliases for Systemic Lupus Erythematosus 4:

Name: Systemic Lupus Erythematosus 4 54
Systemic Lupus Erythematosus, Susceptibility to, 4 13

Classifications:



External Ids:

OMIM 54 608437

Summaries for Systemic Lupus Erythematosus 4

MalaCards based summary : Systemic Lupus Erythematosus 4, also known as systemic lupus erythematosus, susceptibility to, 4, is related to systemic lupus erythematosus and lupus erythematosus. An important gene associated with Systemic Lupus Erythematosus 4 is SLEB4 (Systemic Lupus Erythematosus, Susceptibility To, 4). The drugs Simvastatin and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include skin, endothelial and eye.

Description from OMIM: 608437

Related Diseases for Systemic Lupus Erythematosus 4

Symptoms & Phenotypes for Systemic Lupus Erythematosus 4

Clinical features from OMIM:

608437

Drugs & Therapeutics for Systemic Lupus Erythematosus 4

Drugs for Systemic Lupus Erythematosus 4 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 202)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Simvastatin Approved Phase 4,Phase 1 79902-63-9 54454
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 50-18-0, 6055-19-2 2907
3
belimumab Approved Phase 4,Phase 3,Phase 2,Phase 1 356547-88-1 5957 10451420
4
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
5
Azathioprine Approved Phase 4,Phase 3,Phase 2,Phase 1 446-86-6 2265
6
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2 128794-94-5 5281078
7
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2 24280-93-1 446541
8
Hydroxychloroquine Approved Phase 4,Phase 3,Phase 2 118-42-3 3652
9
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
10
Tacrolimus Approved, Investigational Phase 4,Phase 2 104987-11-3 445643 439492
11
Cilostazol Approved Phase 4 73963-72-1 2754
12
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 53-03-2 5865
13
Metformin Approved Phase 4 657-24-9 14219 4091
14
Sulfamethoxazole Approved Phase 4 723-46-6 5329
15
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
16
Vincristine Approved, Investigational Phase 4 2068-78-2, 57-22-7 5978
17
Alfacalcidol Approved, Nutraceutical Phase 4 41294-56-8 5282181
18
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 2 50-14-6 5280793
19
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 2 1406-16-2
20
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2 59-30-3 6037
21
leucovorin Approved, Nutraceutical Phase 4 58-05-9 143 6006
22 Anticholesteremic Agents Phase 4,Phase 1,Phase 2
23 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
24 Calcium, Dietary Phase 4,Phase 1,Phase 2
25 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4,Phase 1,Phase 2
26 Hypolipidemic Agents Phase 4,Phase 1,Phase 2
27 Lipid Regulating Agents Phase 4,Phase 1,Phase 2
28 Rosuvastatin Calcium Phase 4,Phase 1 147098-20-2
29 Vaccines Phase 4,Phase 2,Phase 3,Phase 1
30 Antibodies Phase 4,Phase 3,Phase 2,Phase 1
31 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1
32 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
33 Hormones Phase 4,Phase 3,Phase 2,Phase 1
34 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
35 Estrogens Phase 4
36 Heptavalent Pneumococcal Conjugate Vaccine Phase 4,Phase 2,Phase 3
37 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
38 Analgesics Phase 4,Phase 2
39 Analgesics, Non-Narcotic Phase 4,Phase 2
40 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
41 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2
42 Antipyretics Phase 4
43 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
44 Cyclooxygenase Inhibitors Phase 4
45 Fibrinolytic Agents Phase 4
46 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
47 Platelet Aggregation Inhibitors Phase 4
48 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2
49 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2
50 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 206)

id Name Status NCT ID Phase Drugs
1 Study of Endothelial Dysfunction in Systemic Lupus and Its Role in Heart Disease Unknown status NCT00188188 Phase 4 quinipril
2 Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in Systemic Lupus Erythematosus (SLE) Patients With Corticosteroid Therapy and High Low-Density Lipoprotein (LDL) Cholesterol Level Unknown status NCT00866229 Phase 4 Rosuvastatin;Simvastatin
3 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
4 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Unknown status NCT00815282 Phase 4 Human papilloma virus vaccine (cervarix)
5 A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE) Completed NCT01597492 Phase 4
6 Immunogenicity and Safety of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With SLE: a Controlled Study Completed NCT00911521 Phase 4 human papillomavirus vaccination (Gardasil)
7 Aspirin and Statins for Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus Completed NCT00371501 Phase 4 Rosuvastatin;placebo;aspirin;placebo
8 Enteric-coated Mycophenolate Sodium Versus Azathioprine for the Extra-renal Lupus Manifestations Completed NCT01112215 Phase 4 Azathioprine;Enteric-Coated Mycophenolate Sodium
9 The Reduction of Systemic Lupus Erythematosus Flares :Study PLUS Completed NCT00413361 Phase 4 versus hydroxychloroquine
10 Effect of Pioglitazone on Endothelial Function in Premenopausal Women With Uncomplicated Systemic Lupus Erythematosus Completed NCT01322308 Phase 4 pioglitazone;placebo
11 Steroid Induced Osteoporosis in Patients With Systemic Lupus Erythematosus Completed NCT00668330 Phase 4 Ibandronate+alfacalcidol+calcium;placebo ibandronate+alfacalcidol+calcium
12 Tacrolimus for the Treatment of Systemic Lupus Erythematosus With Membranous Nephritis Completed NCT00125307 Phase 4 tacrolimus
13 Open-label Trial of Acthar Gel in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus Completed NCT01769937 Phase 4 H.P. Acthar Gel
14 Mycophenolate Mofetil in Systemic Lupus Erythematosus (MISSILE) Completed NCT01101802 Phase 4 Mycophenolate mofetil;sugar pill
15 Effect of Hormone Replacement Therapy on Lupus Activity Completed NCT00392093 Phase 4 Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d
16 Efficacy of Fish Oil in Lupus Patients Completed NCT00828178 Phase 4 Omega-3
17 Lupus Atherosclerosis Prevention Study Completed NCT00120887 Phase 4 Atorvastatin
18 Long-Acting Tacrolimus for the Treatment of Resistant Lupus Nephritis Completed NCT01206569 Phase 4 Long-acting tacrolimus (Advagraf, Astellas Pharma)
19 Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud’s Phenomenon Completed NCT00048776 Phase 4 Pletal
20 The Effect of Metformin on Reducing Lupus Flares Recruiting NCT02741960 Phase 4 metformin;placebo
21 A Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Active Systemic Lupus Erythematosus (SLE) Recruiting NCT02953821 Phase 4 Repository corticotropin injection;Placebo gel
22 Acthar SLE (Systemic Lupus Erythematosus) Recruiting NCT02779153 Phase 4 Acthar low dose (40 U);Acthar high dose (80 U)
23 Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the Absence of Confounding Polypharmacy Recruiting NCT02270970 Phase 4
24 Safety and Immunogenicity of a Zoster Vaccine in SLE Recruiting NCT02477150 Phase 4
25 Prophylactic Trimethoprim/Sulfamethoxazole to Prevent Severe Infections in Patients With Lupus Erythematous Recruiting NCT03042260 Phase 4 Trimethoprim-Sulfamethoxazole;Placebo Oral Tablet
26 A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE Recruiting NCT03098823 Phase 4 RAYOS;Prednisone
27 Low-dose VS High-dose IV Cyclophosphamide for Proliferative LN in Children Recruiting NCT01861561 Phase 4 Low-dose intravenous cyclophosphamide;High-dose intravenous cyclophosphamide
28 ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis Recruiting NCT01926054 Phase 4 Acthar gel
29 ACTHar in the Treatment of Lupus Nephritis Recruiting NCT02226341 Phase 4 CellCept;ACTHar gel;ACTHar gel
30 Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE) Active, not recruiting NCT01632241 Phase 4 Standard therapy
31 Acthar for the Treatment of Systemic Lupus Erythematosus in Patients With a History of Persistently Active Disease Active, not recruiting NCT01753401 Phase 4 Acthar;Placebo for Acthar
32 Belimumab Assessment of Safety in SLE Active, not recruiting NCT01705977 Phase 4
33 Study Title: Assess the Clinical Efficacy of H.P. Acthar Gel 80 U/ml to Improve the Signs and Symptoms in Subjects With Dry Eye Disease Not yet recruiting NCT03287635 Phase 4 H.P Acthar Gel 80Unit/Ml Repository Injection
34 Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases Not yet recruiting NCT03122431 Phase 4 Thalidomide;Hydroxychloroquine reduced;Hydroxychloroquine high
35 Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia Not yet recruiting NCT03229746 Phase 4 Hydroxychloroquine;vincristine;azathioprine
36 Effect of Simvastatin on Endothelial Function in Premenopausal Women With Systemic Lupus Erythematosus (0733-271)(TERMINATED) Terminated NCT00739050 Phase 4 simvastatin;Comparator: Placebo
37 Trial to Study the Effects of Supplementary Omega-3 on Serum C-Reactive Protein Levels Terminated NCT00578578 Phase 4
38 Levothyroxine in Pregnant SLE Patients Withdrawn NCT01276782 Phase 4 Levothyroxine
39 The Effect of Milnacipran on Fatigue and Quality of Life in Lupus Patients Withdrawn NCT01359826 Phase 4 Milnacipran
40 The Efficacy and Safety of Calcitriol for the Treatment of Lupus Nephritis and Persistent Proteinuria Withdrawn NCT00508898 Phase 4 Calcitriol;Multivitamin
41 Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus Completed NCT01408576 Phase 3 Epratuzumab;Epratuzumab
42 A Study of LY2127399 in Patients With Systemic Lupus Erythematosus Completed NCT01205438 Phase 3 LY2127399;Placebo every 2 weeks;Placebo every 4 weeks
43 A Study of LY2127399 in Patients With Systemic Lupus Erythematosus Completed NCT01196091 Phase 3 LY2127399;Placebo every 2 weeks;Placebo every 4 weeks
44 On Open-Label Study in Participants With Systemic Lupus Erythematosus Completed NCT01488708 Phase 3 LY2127399;Placebo
45 Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE) Completed NCT00624338 Phase 2, Phase 3 Atacicept 75 mg;Atacicept 150 mg
46 Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE) Completed NCT01261793 Phase 3 Placebo;Epratuzumab;Epratuzumab
47 Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus Completed NCT01262365 Phase 3 Epratuzumab;Epratuzumab;Placebo
48 Safety Study of Two Vaccine Strategies in Patients With Systemic Lupus Erythematosus Completed NCT00611663 Phase 2, Phase 3
49 Multicenter Study Assessing the Efficacy & Safety of Hydroxychloroquine Sulfate in Patients With Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus With Active Lupus Erythematosus Specific Skin Lesion Completed NCT01551069 Phase 3 hydroxychloroquine (Z0188);Placebo
50 GL701 (Prestara™) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids Completed NCT00082511 Phase 3 Prasterone (GL701)

Search NIH Clinical Center for Systemic Lupus Erythematosus 4

Genetic Tests for Systemic Lupus Erythematosus 4

Anatomical Context for Systemic Lupus Erythematosus 4

MalaCards organs/tissues related to Systemic Lupus Erythematosus 4:

39
Skin, Endothelial, Eye, Bone, T Cells, Testes, B Cells

Publications for Systemic Lupus Erythematosus 4

Articles related to Systemic Lupus Erythematosus 4:

id Title Authors Year
1
Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years of experience. ( 24388428 )
2013

Variations for Systemic Lupus Erythematosus 4

Expression for Systemic Lupus Erythematosus 4

Search GEO for disease gene expression data for Systemic Lupus Erythematosus 4.

Pathways for Systemic Lupus Erythematosus 4

GO Terms for Systemic Lupus Erythematosus 4

Sources for Systemic Lupus Erythematosus 4

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....